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ABSTRACT 
Objective 
We investigated the impact of cervical cell abnormalities detected in the puerperium in association 
with HIV-1 infection on pregnancy outcomes. 
Methods 
A behavioural intervention RCT enrolled 1480 pregnant women (>18years) at a peri-urban 
primary health clinic in South Africa during May 2008-June 2010. A pap smear was performed 
14weeks postpartum and sent to the local laboratory services for cytology. We performed a 
secondary data analysis of pregnancy outcomes, Pap smear results (cytology), HIV results and 
participant demography.  
Results 
564 women (38.1%; 95%CI35.7-40.1) were HIV-1 positive and 78(8.0%; 95%CI6.4-9.9) women 
tested positive for cervical cell abnormalities at the postpartum visit. Forty two (4.2%; 95%CI 
3.1-5.6) women presented with LGSIL, and 7 (0.7%; 95%CI 0.3-1.4) with HGSIL. In an adjusted 
analysis, HIV-infected women were significantly more likely to test positive for LGSIL (p<0.001) 
and HGSIL (p=0.011). Premature birth, low-birth weight and non-live birth rates were similar 
among HIV-infected and uninfected women with abnormal cervical cytology. Low-birth weight 
was also significantly more common among HIV infected women with normal cervical cytology.  
Conclusion HIV-infected pregnant women are more likely to be diagnosed with higher grades of 
squamous cell abnormalities. There is no evidence of an association between squamous cell 
abnormalities/HIV comorbidity and adverse pregnancy outcomes.   
Synopsis 
HIV-infected pregnant women are likely to present with higher grades of cervical cell 
abnormalities in the puerperium but without any evidence of adverse pregnancy outcomes. 
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CHAPTER 1 
INTRODUCTION 
Cervical cancer is the most common malignancy discovered during pregnancy, with an incidence 
of 1.2-4.5 per 10,000 women (Creasman 2001, Duggan 1993). It is the leading cause of cancer 
death in most parts of Sub-Saharan Africa, South America and South Asia (Yang 2004). The 
direct precursor of cervical cancer is represented by Cervical Intraepithelial Neoplasia (CIN), that 
is usually detected and managed through the Papanicolaou (Pap) test cytological screening and/or 
high risk Human Papillomavirus (hr-HPV) DNA testing. 
The incidence of abnormal cervical cytology during pregnancy is at least as high as that reported 
for non-pregnant women. In fact, 1-8% of pregnancies are complicated by an abnormal 
Papanicolaou smears (Insinga 2004).Thus, it is strongly recommended that all pregnant patients 
undergo cervical screening at the time of their initial prenatal visit, as pregnancy can represent a 
unique opportunity to approach otherwise unscreened women (Hunter 2008, ACOG 2002). 
The main documented adverse effect of treated or untreated premalignant lesion in pregnancy is 
preterm birth (Danhof, 2015, Jakobsson 2007, He 2013). Other potential adverse outcome studied 
are miscarriages (Conde-Ferraez 2013), PROM (Cho 2013), stillbirth, and poly/oligohydramnios 
(Ticconi 2013, He 2013). 
 
1.1 RATIONALE FOR THE STUDY 
There is limited data with regards to untreated CIN, HIV and adverse pregnancy outcomes in 
South Africa. We seek to add to the body of available evidence.  
 
1.2. HYPOTHESIS 
Squamous intraepithelial lesions diagnosed in the puerperium is associated with adverse birth 
outcomes. 
1.3. AIM OF THE STUDY 
The overall aim of this study was to describe the prevalence of squamous intraepithelial lesions 
in pregnancy diagnosed in women in the puerperium and investigate associated birth outcomes.  
1.5 .SPECIFIC OBJECTIVES 
• To determine the prevalence of squamous cell intraepithelial lesions in the 
puerperium using routine pap smear screening. 
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• To explore an association between demographic characteristics and squamous 
intraepithelial lesions 
• To describe clinical characteristics (Parity, contraception, CD4+ Count) in women 
presenting with squamous cell intraepithelial lesions in the puerperium. 
• To describe potential relationships between squamous cell intraepithelial lesions and 
other STIs including HIV 
• To compare Perinatal outcomes [Preterm birth (PTB), Low Birth weight (LBW), and 
Stillbirth (SB)] in women presenting with and without squamous cell intraepithelial 
lesions. 
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CHAPTER 2 
LITERATURE REVIEW 
 
2.1. Definitions  
 Cervical Intraepithelial Neoplasia (CIN): The direct precursor of cervical cancer is 
represented by Cervical Intraepithelial Neoplasia (CIN), that is usually detected and managed 
through the Papanicolaou (Pap) test cytological screening and/or high risk Human 
Papillomavirus (hr-HPV) DNA testing. 
Atypical squamous cells of undetermined significance (ASC-US): ASC-US means that 
changes in the cervical cells have been found. Squamous cells are thin and flat and grow on the 
surface of a healthy cervix. In the case of ASCUS, the Pap smear reveals slightly abnormal 
squamous cells, but the changes don't clearly suggest that precancerous cells are present. The 
changes are almost always a sign of an HPV infection. ASC-US is the most common abnormal 
Pap test result.  
Low-grade squamous intraepithelial lesion (LGSIL): LGSIL means that the cervical cells 
show changes that are mildly abnormal. LSIL usually is caused by an HPV infection that often 
goes away on its own. 
High-grade squamous intraepithelial lesion (HGSIL): HGSIL suggests more serious changes 
in the cervix than LGSIL. It is more likely than LGSIL to be associated with precancer and 
cancer.  
Preterm Births: Births occurring <37 weeks gestation were defined as preterm.  
 
Low Birth Weight: Low birth weight was defined as <2500g in term deliveries >37 weeks 
gestation. 
 
Stillbirth: Stillbirths are defined as foetal demise > 21 weeks gestational age.  
 
Miscarriage: A miscarriage is defined as foetal demise <21 weeks. 
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2.2. Epidemiology of Cervical Intraepithelial Neoplasia 
A total of 715 000 cases of cancer were newly diagnosed in 2008 alone in Africa. Cervical cancer 
was the commonest type of cancer in women in sub-Saharan Africa (31.7/100 000) (Jemal 2012). 
In Southern Africa, cervical cancer was the 2nd commonest type of cancer in women, second to 
breast cancer (26.8/100 000). Accordingly, cervical cancer was the leading cause of cancer-related 
deaths in women in SSA (22.5/100 000) and the second leading cause of cancer related deaths in 
Southern Africa (14.8/100 000).  Pap test screening (organized or opportunistic) allows the 
detection and removal of precancerous lesions (Bray 2005, Parkin 2008, Mathew 2009, Vizcaino 
2000). In several western countries, where screening programs have long been established, 
cervical cancer rates have decreased by as much as 65% over the past four decades. For example, 
in Finland, cervical cancer incidence rates decreased from 21.1 in 1966 to 7.3 in 2007 (IARC 
2007).  
 
2.3. Risk Factors for Cervical Intraepithelial Neoplasia  
 
Human papillomavirus (HPV), a sexually transmitted infection, is clearly established as a 
necessary agent in the development of cervical cancer (La Ruche 1998, Smith 2003, Kumar 2005, 
Baseman 2005, Castellsague 2002, Hawes 2003, Shapiro 2003, Walboomers 1999). There is 
increasing evidence that HPV increases risk of HIV acquisition, ie. women who are HIV infected 
are more likely be infected with HPV too. Being HIV positive, women have a higher prevalence 
of HPV across all age groups and more particularly in the reproductive age. HPV prevalence in 
HIV positive women was 74% as compared to 36.7% in HIV negative women (Mbulawa 2015).  
Pregnancy seems to be a risk factor for cervical HPV infection or increased replication of the 
persisting virus due to the associated increased hormonal level or immunosuppression 
(Castellsague 2006). Persistent infection with about 15 high-risk human papillomavirus (HPV) 
types is the major risk factor for cervical cancer, with HPV-16 and HPV-18 infections accounting 
for about 70% of the total cases (Castellsague 2006).  
 Exposures related to sexual and reproductive behaviour play an important role in the aetiology 
of cervical cancer. Other established risk factors include smoking, increasing parity, early age at 
first intercourse, multiple sexual partners, and infection with other sexually transmitted diseases 
(Smith 2003, Kumar 2005, Baseman 2005, Castellsague 2002, Cooper 2007).   
Hormonal contraceptives also seem to increase the risk of cervical cancer in most populations 
studied. A recent meta-analysis by the International Collaboration of Epidemiological Studies of 
Cervical Cancer included 24 studies conducted worldwide (Appleby 2007). It found elevated risk 
of cervical carcinoma associated with both oral and injectable contraceptives, increasing with 
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duration of use. Some studies of populations in sub-Saharan Africa, however, have not shown 
increased risk (Shapiro 2003, Appleby 2007).  
 
2.4. Natural History of Cervical Intraepithelial Neoplasia in Pregnancy 
There is no evidence to suggest that pregnancy increases the rate of CIN progression to invasive 
carcinoma, it occurs in 0% to 0.4% of cases; most of the intraepithelial dysplastic lesions remain 
stable or regress. Spontaneous regression occurs in 48% to 70% of HGSIL (High Grade 
Intraepithelial lesion) or CIN2-3 lesions (Yost 1999, Paraskevaidis 2002, Ahdoot 1998, 
Coppolillo 2013). The effect of delivery mode on regression of dysplastic lesions remains 
controversial (Yost 1999, Coppolillo 2013, Kaplan 2004, Brinton 1989, Kaneshiro 2005). Ahdoot 
et al reported a spontaneous regression in 60% of women with HSIL who had a vaginal delivery, 
whereas none of the patients who delivered by caesarean section showed regression (Ahdoot 
1998). On the other hand, Yost et al found an overall regression of HSIL lesions in 70% of 
patients, irrespective of the mode of delivery (Yost 1999). It has been speculated that the cervical 
trauma occurring during second and third stage of labour and during delivery can lead to an 
inflammatory reaction in the cervix epithelium which can promote repair mechanisms. Another 
theory advocates the transient ischemic changes occurring to cervical tissues during ripening as 
responsible of lesions regressions. 
 
2.5. Epidemiology of HIV in Pregnancy in South Africa 
The role of HIV in the aetiology of cervical cancer is also unclear, especially in Africa. 
Immunosuppression is a risk factor for HPV infection and/or detection, and there is consistent 
evidence that HIV-positive women have higher prevalence of HPV infection, more persistent 
infection, and resulting higher rates of preinvasive cervical lesions (Chirenje 2005, La Ruche 
1998, Baseman 2005, Castellsague 2002, Ferenczy 2003, Wright 1994, Rowhani-Rahbar 2007).  
South Africa has the largest burden of HIV disease globally (UNAIDS 2014). The national 
antenatal HIV prevalence in 2013 was 29%, but within South Africa itself, the HIV epidemic is 
heterogeneous and KZN still maintains the highest antenatal HIV prevalence (40%) record over 
the past 2 decades (National Dept of Health, SA 2015) (Figure 1).  
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Figure 1 Provincial Antenatal HIV Prevalence in South Africa (2012) 
 
And within KwaZulu Natal itself, the antenatal HIV prevalence ranges from 36% to 45%; with 
eThekwini being among the four highest burden districts (HIV prevalence >40%) (Figure 2). 
 
 
 
Figure 2 District Antenatal HIV Prevalence in KwaZulu Natal (2012) 
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South Africa has through its expansive PMTCT programme initiated more women than males on 
ART. The effect of this can be seen in the antenatal seroprevalence trend. The prevalence in the 
older age groups is reflective of established infections, with the increase in prevalence in the older 
age groups (>35) due to greater antiretroviral treatment access and increased survival and 
increased parity among women with established HIV infections (National Dept of Health, SA 
2015) (Figure 3). 
 
 
Figure 3 HIV Prevalence of Pregnant Women by Age in South Africa 
 
2.6 Pregnancy Outcomes in South Africa 
 
Prior to the antiretroviral rollout in South Africa, the 2003-2005 Saving Babies Report included 
data for 576,065 births in public health institutions in South Africa each year (MRC Research 
Unit for Maternal and Infant Health Care Strategies, 2007). The perinatal mortality rate was 
reported as 37.5 cases per 1000 births. The stillbirth, early neonatal death and low birth weight 
rates were 24.3, 12.2 and 15.5 cases per 1000 births respectively. 
Since the antiretroviral rollout, the 2010-2011 Saving Babies Report included data for 1,324,320 
births ((MRC Research Unit for Maternal and Infant Health Care Strategies, 2013). The 
cumulative perinatal mortality rate was reported as 25.6 per 1000 births, a significant drop in 
perinatal deaths since the pre-ARV Report. Similarly, the stillbirth and early neonatal death were 
significantly lower than that reported in the pre-ARV period (stillbirth 18.5 cases per 1000 births 
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and early neonatal deaths 7.2 cases per 1000 births). However, there was no significant reduction 
in the low birth weight rate (14.2 cases per 1000 births).  
Neither of these reports attributed the adverse birth outcomes to HIV. Only recently, in a 
hospital audit of 10372 deliveries, Moodley et al reported 301 (2.9%) still births, 2241 (21.8%) 
preterm deliveries , 469  (4.6%) very preterm delivery , 1458 (14.1%) low birth weight , 349 
(3.4%) very low birth weight and 870 (8.5%) were small for a given gestational age  based on 
their birth weight being below the 10th percentile (Moodley 2016). In this analysis, unregistered 
pregnancies and HIV infection remained significant risk factors for still birth (OR 6.84 and 1.34 
respectively), preterm deliveries (OR 1.30 and 4.44 respectively), low birth weight (OR 1.33 
and 4.25 respectively) and small for gestational age (OR 1.2 and 2.31 respectively). The authors 
concluded that, when compared to HIV uninfected women, HIV infected women had a higher 
risk for stillbirth, PTD, SGA, and LBW babies. In addition, the audit confirmed that ART 
exposure as ZDV prophylaxis or triple ARV regimen was associated with a decreased odds of 
risk for an adverse birth outcome.  
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CHAPTER 3 
METHODOLOGY 
3.1 Study setting 
The Umlazi Section D clinic is a primary health care (PHC) centre in Durban and is situated 17 
Km Southwest of Durban.  The population of it is estimated at 900 000 although some estimates 
indicate a higher population figure – up to 1.6 million people.  There are informal shack 
settlements in and the surrounding areas.  It is a community that amplifies South Africa’s 
already-significant HIV rate. Most women are seen at the Umlazi Section D Clinic for all 
antenatal clinic visits, and then they deliver their babies at the Prince Mshiyeni Memorial 
Hospital.  All post-natal visits and well-baby visits are conducted at the Section D clinic.  The 
PHC clinic has an active PMTCT program.  Most women start their ANC visits at 14-28-weeks 
gestation, and women are usually offered HIV testing at their first visit. Women are given 
standard HIV post-test counselling according to WHO/CDC guidelines in the form of group 
counselling with 8-10 other women from the ANC clinic. Those who agree to be tested are 
tested using rapid testing technologies.  All women are given standard HIV post-test 
counselling.     
 
3.2. Study Design 
This dissertation is based on a secondary analysis of data collected during a randomized 
controlled intervention study, the South African HIV Antenatal and Postnatal Support 
(SAHAPS) study (Maman 2014). The SAHAPS study was a collaborative study between the 
University of KwaZulu-Natal and the University of North Carolina at Chapel Hill and was 
designed to examine the efficacy of  enhanced HIV counselling and support for pregnant 
women in reducing sexual behaviour risk during pregnancy and postpartum. The primary 
outcome measures were STI incidence (Trichomonas vaginalis, Neisseria gonorrhoea and 
Chlamydia), consistent and correct condom use, and partner uptake of HIV VCT. The parent 
study was sponsored by the National Institute for Health and Child Development (NICHD), 1-
R01-HD050134001-A1. 
 
3.3. Regulatory Approvals 
The parent study was approved by the Institutional Review Boards of the University of KwaZulu-
Natal and the University of North Carolina at Chapel Hill. A written informed consent was 
obtained from all women who participated in the main study. For the secondary analysis a separate 
submission to the University of KwaZulu Natal IRB was approved (IRB# BE 476/15). 
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3.4 Study Population 
There are about 9,000 first visit antenatal attendees per year at Umlazi SED Clinic. Women 
range in age between 16 and 40 years. Approximately 25% are primigravid and the average 
gestational age at first visit is 24 weeks. Pregnant women who presented to the Umlazi Section 
D clinic for antenatal care were screened for participation in the parent study (South African 
HIV Antenatal and Postnatal Study – SAHAPS study) (Maman 2014). 
 
3.4.1 Inclusion Criteria:  
• at least 18 years old 
• had never tested for HIV or had tested negative for HIV at least 3 months prior to 
recruitment 
• planned to live in Durban for at least the next year 
• planned to bring their infant to the clinic for immunization visits 
 
3.4.2 Exclusion Criteria: 
• not willing to participate in the study 
• we’re not able to communicate in English or isiZulu 
• did not have a primary intimate partner for atleast the past 6 months 
• had a pregnancy complication that needed referral to a higher level of care 
 
3.5 Sample Size 
The main study was powered to allow for all statistical analyses to be stratified by HIV-status 
because the content of the enhanced counseling intervention differed for these two groups. 
Based on a 9% difference in incidence rate of STIs among HIV-positive women in the 
intervention and control arms and an 8% difference among HIV-negative women, 279 HIV-
positive and 295 HIV-negative participants per group were needed for 80% power. For 
consistent condom use, this sample size has the power to detect a difference between groups of 
12% for HIV-positive women and 11% for HIV-negative women.  
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3.6 Participant Flow in the SAHAPS Study (Parent Study) 
Between May 2008 and June 2010, first visit antenatal attendees, who were eligible and 
consented to participate in the SAHAPS study had a baseline survey (demographics and sexual 
behaviour) administered, were tested for HIV, randomized to the control or intervention arm 
and screened for other STIs (N. Gonorrhoea, C. trachomatis, and T.vaginalis). Women received 
the standard antenatal care throughout pregnancy and the standard HIV PMTCT/Treatment care 
according to the South African guidelines for that period. At 6 and 10 week postpartum visits 
we conducted a medical chart review of obstetric outcomes, and provided intervention 
counselling sessions to women randomized to the intervention arm (Figure 4). At the 14 week 
postpartum visit we conducted a behavioural survey, performed a pap smear and repeated the 
STI screening.  At 9 months postdelivery, a post-intervention survey was conducted and 
participants exited the study.  
 
 
Figure 4:  Participant Flow and Key Procedures in the SAHAPS Study (Parent Study) 
 
3.7 Data Collection 
For the SAHAPS study (parent study) a medical extraction form (Appendix 7) was developed to 
include participant demographics, pregnancy outcomes, STI results, PAP Smear Results, and HIV 
Status. The study nurses examined the maternity chart and infant’s road-to-health card to obtain 
1st Antenatal Visit  
Informed Consent
Baseline Survey
STI Screening
Randomisation
6 and 10 weeks 
Postpartum
Intervention Sessions
Pregnancy Outcomes
14 weeks Postpartum 
Behavioural Survey
STI Screening
Pap Smear
Medical Chart Review
9 Months 
Postpartum
PostIntervention 
Survey
12 
 
pregnancy outcomes. The study nurses performed HIV testing, and maintained their own record 
of participant’s HIV status, in addition to documenting the status in the maternity chart. Formal 
laboratory results were obtained for STIs and Pap smear, these results were transcribed onto the 
medical extraction forms (Appendix 7). Data capturers entered data from the medical extract 
forms onto a specifically designed database on ACCESS.  
 
3.8 Statistical Analysis 
Data for 1480 participants were captured in a database in real time and for the purpose of this 
secondary analysis select variables were imported into an Excel Spreadsheet. The variables 
included demographic characteristics, HIV status, obstetric history and characteristics, birth 
outcomes, cervical cytological results for Pap smear screening and laboratory STI 
investigations.  
List of Categorised Variables Extracted from Main Database 
Age 
<20                         
20-25 
26-35 
>35 
 
Education 
No formal School 
Primary 
Secondary 
 
Previous Pregnancies 
0 
1.-2 
>3 
 
Chlamydia 
Neiserria 
Trichomonas 
 
Negative 
Inconclusive 
ASC-US 
LGSIL (CIN1/HPV) 
HGSIL (CIN2/3) 
 
Birth Outcomes 
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Live Births 
Still Births 
 
Birth Weight 
<2500g 
>2500g 
<1500g 
Gestational Age at Delivery 
<37w 
>37w 
<34w 
 
HIV Clinical Stage 
Stage 1 
Stage 2 
Stage 3/4 
 
Data were analysed using Stata 13.0 SE (StataCorp. 2013. Stata Statistical Software: Release 
13. College Station, TX: StataCorp LP). Ninety five (95) % confidence intervals were 
constructed around prevalence point estimates i.e. prevalence of CIN in puerperium. 
Assessment of association between continuous demographic and clinical characteristics by CIN 
status was assessed using the standard t-test or non-parametric Wilcoxon rank-sum test if the 
normality assumption is not upheld for the latter. Correlation between continuous variables was 
assessed using the Pearson correlation coefficient or Spearman rank correlation coefficient. 
Differences in frequencies of categorical demographic or clinical characteristics by CIN status 
and association with perinatal outcomes were assessed using the Pearson chi-square (χ2) test or 
Fisher’s exact test if an expected cell count contains fewer than 5 observations. Multivariable 
logistics regression was employed to assess factors associated with CIN after controlling for the 
confounding influence of other covariates. Model fit and validity were confirmed. An adjusted 
p-value of <0.05 was deemed statistically significant.  
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CHAPTER 4 
RESULTS 
 
4.1 Squamous Intraepithelial Lesions in the Study Population 
Of the 1480 pregnant women enrolled in the SAHAPs study, 564 (38.1%; 95%CI 35.7-40.1) 
women tested HIV positive at their first antenatal visit. Pap smear results were not available for 
471 (31.8%) women in this cohort.  Among the 1009 women who had a Pap smear result in the 
postpartum period, categorization was not possible for 36 (3.6%) and 895 (88.7%) women had 
normal smears. The HIV prevalence (31.4% vs 32.5%; p=0.720), age distribution (50.0% vs 
52.0% <25; p=0.468), non-live births (3.8% % vs 3.8%; p=1.000), preterm births (18.9% vs 
18.8%; p=0.942) and LBW (4.2% vs 2.9%; p=0.205) were comparable between women who had 
a Pap smear result and those who did not.  Of the 1009 women with a Pap smear result at the 
postpartum visit, 78 (8.0%; 95%CI 6.4-9.9) women tested positive for squamous cell 
abnormalities. Abnormalities included 29 atypical (ASC-US) cases (2.9%; 95%CI 2.0-4.1), 42 
(4.2%; 95%CI 3.1-5.6) cases of LGSIL or HPV infection, and 7 (0.7%; 95%CI 0.3-1.4) cases of 
HGSIL (Figure 5).  
 
Figure 5 Distribution of Pap smear Results for Women in the Puerperium (n=1009) 
The mean age of women presenting with some form of squamous cell abnormality was 24.9 years 
(+4.9), which did not differ significantly from women with no abnormalities (25.7 + 5.4 years). 
3,6
88,7%
2,9
4,2 0,7
Categorisation not Possible Normal Smears ASC-US LGSIL HGSIL
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Younger women (≤24years) had a higher prevalence of LGSIL (4.8% vs 3.5%) while the older 
women (>24) had a higher prevalence of HGSIL (1.2% vs 0.2%) (p=0.550) (Table I). 
 
4.2 Squamous Intraepithelial Lesions and HIV 
After adjusting for age group, education, socio-economic status and other STIs in the 
multivariable analysis, women with HIV infection were significantly more likely to test positive 
for LGSIL or HGSIL (Table I). 34 of the 1009 (3.4%) women with a Pap smear result were HIV 
positive and also tested positive for squamous cell abnormalities. When compared to HIV 
uninfected women postpartum, the prevalence of LGSIL and HGSIL were three (7.6% vs 2.3%) 
and eightfold higher (1.6% vs 0.2%) among HIV-infected women respectively (p<0.0.001) 
(Figure 1). HGSIL was also significantly more common among women who had more than 1 
pregnancy (p=0.023) (Table I). 
 
4.3 Squamous Intraepithelial Lesions and Pregnancy Outcome 
Pregnancy outcome data were available for 829 (82.2%) women with a Pap smear result. There 
were 8 miscarriages (1.09%; 95%CI 0.57-2.06); 17 stillbirths (2.18%: 95%CI 1.38-3.42) and 4 
neonatal deaths (0.48%; 95%CI 0.19-1.24). Among the 800 live births, 91 were born prematurely 
(17.19%; 14.72-19.98) and 27 newborns were of low-birth weight (3.96%; 95%CI 2.69-5.77). 
There were no birth weight and preterm data for 57 (7.1%) and 14 (1.7%) newborns respectively. 
When comparing birth outcomes among HIV infected to HIV uninfected women, the proportion 
of livebirths (96.33% vs 96.16%; p=0.558), low birth weight (5.14% vs 3.14%; p=0.103) and 
preterm births (18.52% vs 19.0%; p=0.448) were not significantly different.  
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Table I: Characteristics of Women with and without squamous cell abnormalities in the 
Puerperium 
 ASC-
US 
(n=29) 
Diagnosi
s 
Deferred 
(n=36) 
HGSIL 
 
(n=7) 
LGSIL 
(CIN1/HP
V) 
(n=42) 
Normal 
(n=895) 
Unadjusted 
P value 
Adjusted 
P value 
Age group        
<24 18 (3.6) 22 (4.4) 1 (0.2) 24 (4.8) 436 (87.0) 0.072 0.548 
>24  11 (2.2) 14 (2.8) 6 (1.2) 18 (3.5) 459 (90.4)   
Education        
No Formal 
School 
3 (5.1) 1 (1.7) 0 (0.0) 1 (1.7) 54 (91.5) 0.405 0.749 
Primary 9 (2.2) 13 (3.2) 5 (1.2) 18 (4.4) 368 (89.1)   
Secondary 17 (3.2) 22 (4.1) 2 (0.4) 23 (4.3) 472 (88.1)   
Socieconomic 
Status 
       
Low 11 (2.9) 15 (3.9) 2 (0.5) 16 (4.2) 338 (88.5) 0.709 0.503 
Moderate 12 (3.1) 13 (3.4) 3 (0.8) 19 (4.9) 339 (87.8)   
High 5 (2.3) 8 (3.7) 2 (0.9) 6 (2.8) 197 (90.1)   
Previous 
Pregnancies 
       
0 17 (4.7) 1 (0.3) 1 (0.3) 17 (4.7) 310 (85.9) 0.035* 0.023* 
1-2 6 (1.6) 4 (1.1) 4 (1.1) 19 (5.1) 329 (88.2)   
>3 6 (2.2) 2 (0.7) 2 (0.7) 6 (2.2) 256 (93.1)   
HIV Status        
Negative 18 (2.9) 25 (3.9) 1 (0.2) 14 (2.2) 570 (90.8) <0.001* <0.001* 
Positive 11 (2.9) 11 (2.9) 6 (1.6) 28 (7.4) 325 (85.3)   
N.gonorrhoea
e 
       
Negative 28 (3.0) 32 (3.4) 6 (0.6) 39 (4.1) 836 (88.8) 0.766 0.714 
Positive 1 (1.8) 4 (7.1) 1 (1.8) 2 (3.6) 48 ((85.7)   
C.trachomatis        
Negative 25 (3.1) 30 (3.7) 6 (0.7) 34 (4.2) 723 (88.4) >0.99 0.412 
Positive 4 (2.2) 6 (3.3) 1 (0.6) 8 (4.4) 161 (89.4)   
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In a separate bivariate analysis (Table II), birth outcomes were compared between women with 
and without cytological abnormalities. Similarly no marked differences in the prevalence of low 
birth weight babies and non-live births in these comparator groups of women was identified 
(Table II). Although the proportion of preterm births was higher among women with HGSIL (3 
of 7; 42.9%) as compared to women with LGSIL (7 of 39; 17.9%), ASC-US (4 of 29; 13.8%) or 
Normal Cytology (152 of 812; 18.7%), this association was not statistically significant (p=0.222).  
Table II: Pregnancy Outcomes in Women with and without squamous cell abnormalities 
in the Puerperium 
  
 ASC-
US 
(n=29) 
HGSIL 
 
(n=7) 
LGSIL  
(n=39) 
Normal 
(n=812) 
Unadjusted 
P value 
Total   
N 
Birth Outcomes (n=829) n (%) n (%) n (%) n (%)   
Miscarriage  0 (0.0) 0 (0.0) 1 (12.5) 7 (87.5) 0.938 8  
Stillbirth 1 (5.9) 0 (0.0) 0 (0.0) 16 (94.1)  17 
Livebirth 25 (3.1) 7 (0.9) 34 (4.3) 734 (91.8)  800 
Birth Weight (n=743)       
<2500g 3 (5.2) 2 (3.4) 0 (0.0) 53 (91.4) 0.094 58  
>2500g 21 (3.1) 5 (0.7) 31 (4.5) 628 (91.7)  685 
Gestational Age at 
Delivery (n=786) 
      
Preterm <37weeks 3 (5.0) 2 (3.3) 2 (3.3) 53 (88.4) 0.222 60  
Term  > 37weeks 22 (3.0) 5 (0.7) 31 (4.3) 668 (92.0)  726 
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4.3 HIV-1 Infection, Squamous Intraepithelial Lesions and Pregnancy Outcomes  
In comparing pregnancy outcomes among HIV infected and uninfected women with a cytological 
abnormality, premature birth rates, low birth weight and live birth rates were similar across all 
groups (Table III). Low birth weight frequency however was significantly higher among HIV 
positive women with normal cytological results when compared to their HIV negative 
counterparts (6.9% vs 3.1%; p =0.032). 
 
Table III: Pregnancy Outcomes in Women with and without squamous cell abnormalities 
and/ or HIV Infection in the Puerperium 
 
 
 
  
 ASC-US 
(n=29 
 
HGSIL 
 
(n=7) 
LGSIL  
(n=42) 
Normal Pap 
Smear 
(n=895) 
HIV Status Pos 
(n=11) 
Neg 
(n=18) 
Pos 
(n=6) 
Neg 
(n=1) 
Pos 
(n=28) 
Neg 
(n=14) 
Pos 
(n=325) 
Neg 
(n=570) 
Birth Outcomes          
Non-Live Births n 
(%) 
0 (0.0) 1 (6.7) 0 (0.0) 0 (0.0) 0 (0.0) 1 (8.3) 11 (4.2) 12 (2.6) 
Live Birth 11 14 6 1 22 12 267 467 
p value 0.345 - 0.371 0.183 
Birth Weight         
<2500g n (%) 2 (0.0) 1 (0.0) 1 (0.0) 1 (0.0) 0 (0.0) 0 (0.0) 29 (6.9) 31 (3.1) 
>2500g 8 14 5 0 20 11 222 418 
p value 0.345 0.285 - 0.026* 
Gestational Age at 
Delivery 
        
Preterm 37weeks  n 
(%) 
2 (27.3) 1 (7.1) 1 
(33.3) 
1 
(100) 
4 (19.0) 1 (0.0) 31 
(15.9) 
50 
(17.9) 
Term  > 37weeks 9 17 5 0 22 12 265 468 
p value 0.316 0.285 0.185 0.396 
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Figure 6: Proportion of HIV positive women in each category of Squamous Cell 
Abnormalities and Women with a normal pap smear  
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CHAPTER 5 
DISCUSSION 
 
 
A Pap smear routinely performed approximately 3 months postpartum revealed cervical 
squamous cell abnormalities in 8% of the study population. This is consistent with reported 
incidence in pregnancy of 1-8% (Insinga 2004, Palle 2000, Campion 1993, Baseman 2005). 
Variance in rate is related to diagnostic methods used, viz colposcopy directed biopsy confirmed 
versus Pap smear only. CIN lesions are secondary to persistent oncogenic HPV infection 
(Schlecht 2001). The sensitivity of Pap smear for SIL is 70-80% (Sherman 1998). The role of 
colposcopy diagnosis in pregnancy is to exclude micro invasive disease. Once micro invasive 
disease has been excluded, patients are managed expectantly until puerperium (Yost 1999, Vlahos 
2002, Paraskevaidis 2002, Massad 2013). Persistence of SIL into the puerperium is reported to 
be in the region of 40-60% with regression rate of 48-70% (Yost 1999, Paraskevaidis 2002, 
Ahdoot 1998, Coppolillo 2013).  
The timing of screening in pregnant women could be another potential reason for varying 
prevalence rates. Some studies presented findings from screening in pregnancy, while other 
studies including our study have presented findings from screening in the postpartum period 
(Kaplan 2004). However, there is evidence that non-invasive CIN diagnosed in pregnancy have 
a higher tendency not to progress during pregnancy and there is a high likelihood of these cases 
even regressing to a complete remission after delivery (48-70%) (Paraskevaidis 2002, Yost 1999). 
Only high grade CIN is more likely to persist postpartum and our prevalence of HSIL in the 
postpartum women (0.7%) is higher than most other reported studies of pregnant women (0.4%) 
(Kaplan 2004). A large population based study in Brazil also confirmed that HSIL prevalence 
(0.4%) in pregnant women was similar to their non-pregnant counterparts (Meyrelles 2013). 
 Of significance, older women with more than one pregnancy were more likely be diagnosed with 
HGSIL while younger women were more likely to present with atypical squamous cell appearance 
and LGSIL. Higher parity (≥ 3) was inversely associated with squamus cell abnormalities. This 
is in contrast to other studies that have found an increased rate of CIN/cervical cancer with 
increasing parity (Hildesheim 2001, Munoz 2002). However other studies found that parity had a 
borderline or no association with CIN/cervical cancer (Deacon 2000, Kruger-Kjaer 1998, Bhatla 
2013). The plausible mechanism for high parity and increased risk of CIN, is postulated to be due 
to increased oestrogen in pregnancy leading to increased exposure of transformation zone to HPV 
and other cofactors over a prolonged period of time. Furthermore immune modulation in 
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pregnancy may promote persistence and progression of cervical dysplasia (Munoz 2002, Mathew 
2009, Vizcaino 2000). 
There are few studies that investigated the association between CIN and HIV in pregnancy, but 
most studies did not compare their findings to a HIV uninfected group of pregnant women 
(Meyrelles 2013, Mayaud 2001).  In our study HIV infection was associated with a 3-fold increase 
in LSIL and eight-fold increase in HSIL in postpartum women. This association between HIV 
and cytological abnormalities is consistent with findings from two other South African studies of 
non-pregnant women and this could mainly be related to an increased persistence of high risk 
HPV infections in HIV-infected women (Wang 2011).This is consistent with findings by 
Firnhaber et al as well as Denny et al (Denny 2008, Firnhaber 2009) which is mainly related to 
increased persistence of high risk HPV infections in HIV-infected women (Sun 1997). In addition, 
HIV infected women may be set by local cervical immunological dysfunction increasing their 
likelihood of acquiring HPV infection (Wang 2011). 
The underlying pathogenesis of HPV infection has been associated with preterm births (Al-Halal 
2013, Mosbah 2017). Few studies have reported higher rates (10.7-12.2%) of preterm deliveries 
in untreated women with CIN (Sadler 2004, Spitzer 1995). A large study by Bruinsma et.al in 
2007 which included a comparison with the general population showed an increase rate of preterm 
deliveries (Bruinsma 2007). A recent study published in 2013 from Beijing, also showed 
increased in PTB rate, as well as an increase in caesarean section and oligohydramnios in 
untreated women with CIN (Yue 2013).These findings suggest that characteristics of the woman 
or underlying pathological changes may render the woman with CIN susceptible to preterm 
delivery (Bruinsma 2007). 
There was no association between SIL and age, educational status, which is concordant with 
finding by another study (Ellen 1991). 
There was no association between SIL and STIs in this study. This is not surprising given the 
conflicting evidence of this association in the various publication. Some studies have reported a 
strong association especially with Chlamydia (Madeleine 2006, Smith 2004, Gopalkrishna 2000, 
Lehmann 1999) whilst others reported no association with any STIs (de Paula 2007, Castle 2003). 
Generally, infections and associated morbidity in pregnancy are likely to alter pregnancy 
outcomes. Yet, there was no evidence of greater adverse pregnancy outcomes among HIV 
infected women with cervical cell abnormalities in our South African study cohort. Only a handful 
of studies have reported pregnancy outcomes for a population with cervical cell abnormalities, 
and none of these explored the outcomes in HIV co-infected pregnant women. Findings from 
these limited studies were suggestive of an association between preterm deliveries and CIN/HPV. 
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Our study findings appear reassuring and suggest that HIV and LGSIL or HGSIL do not alter 
pregnancy outcomes.  We have previously shown that untreated sexually transmitted infections 
in pregnancy are more likely associated with adverse pregnancy outcomes (Moodley 2017). 
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CHAPTER 6: CONCLUSION 
In conclusion, we confirm that HIV-infected postpartum women are more likely to be diagnosed 
with higher grades of cervical cell abnormalities. We further confirm that cervical cell 
abnormalities are not associated with adverse pregnancy outcomes. 
6.1 RECOMMENDATIONS 
Pap smears screening may be deferred to the postpartum period given the low prevalence of 
HGSIL at the postpartum visit and lack of association between birth outcomes and HGSIL/HIV 
comorbidity. There is also a need for additional studies to review the impact of the recent HPV 
vaccination programme in South Africa. 
 
6.2 LIMITATIONS 
There are several limitations in our study as a result of a retrospective data analysis. This 
included missing pregnancy outcome data, Pap smear results were not available for a large 
proportion of the study population and the lack of quality control measures in the performance of 
Pap smears.  
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Appendix 7: Data Extraction Form (SAHAPS)  SOUTH AFRICAN HIV ANTENATAL POSTTEST SUPPORT (SAHAPS) STUDY     MEDICAL CHART EXTRACTION FORM  VISIT: BASELINE (ANTENATAL)   
Study Screening # S 0 0 1    
Antenatal Number #        
 
Date of Visit       
      D            D          M        M          Y Y 
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DURATION OF HIV COUNSELING SESSIONS:  
 
1st Post-test Counseling session BASELINE:  
Date of 1st post-test counseling session:  __  __/__  __/__  __  
     D  D  M  M  Y  Y 
 
Time that the consultation started: ___________    Time HIV counseling started: 
___________ 
Time consultation ended: ___________    Time HIV counseling ended: 
___________    
 
DEMOGRAPHICS 
DMG1. Date of Birth?   1.  ___ ___ ___ ___ ___ ___ ___  
        D     D     M   M   M    Y    Y 
 
88. If DOB unknown: Age (Yrs) _________________________ 
DMG2. Gestational Age at First 
Antenatal Visit 
 
1. LMP  weeks 
2. US      weeks 
3. Palp    weeks 
4. SFH   weeks 
__________________ 
DMG3. EDD  
_ ___ ___ ___ ___ ___ ___ ___  
   D     D     M   M   M    Y    Y 
 
DMG4. Parity  
   
DMG5. Gravidity  
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HISTORY OF SEXUALLY TRANSMITTED INFECTIONS  
RISK1.  History of STI in the past 
year 
No    Yes   Don’t know  
 
RISK2History of Abnormal Vaginal 
Discharge in the Past Year  
 
Never  Once   Twice  More than twice  Don’t  know  
 
RISK3.  History of genital sore or 
ulcer in the Past Year.  
 
Never  Once  Twice  More than twice  Don’t  know  
 
 
INFANT FEEDING 
IF1. Intended feeding method in ANC? 1. exclusive breastfeed  
2. exclusive formula   
3. Other   specify___________________________________ 
88. don’t know yet   
 
SEXUALLY TRANSMITTED INFECTIONS IN CURRENT PREGNANCY 
ST1.  STI Lab 
Investigations  
Done 
 
RPR      Yes  No   
  
TPHA   Yes  No   
 
CVS – Neisseria gonorrhea      Yes  No   
 
CVS – Trichomonas vaginalis  Yes  No   
 
CVS - Chlamydia trachomatis   Yes  No   
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ST2.  STI Lab 
Investigations  
Results 
 
RPR Negative Positive Inconclusive Inadequate Specimen    
 
TPHA Negative Positive Inconclusive Inadequate Specimen 
 
CVS – N. gonorrhea Negative Positive Inconclusive Inadequate Specimen 
 
CVS T. vaginalis Negative Positive Inconclusive Inadequate Specimen 
 
CVS C. trachomatis Negative Positive Inconclusive Inadequate Specimen 
 
ST3.  Clinical Signs 
of STI 
(Discharge/ulcer 
etc)  
 
Yes  No 
ST4. PAP smear 
done 
 Yes  No    
 
ST5. If Yes Results 
 
HIV RELATED 
HR1. HIV Tested Today Yes  Refused 
If Yes SKIP to HR2.  
HR2. If refused, why?   Did not perceive herself to be at risk   Afraid to test 
  Tested before   To discuss with partner 
  Other ____________________________________ 
SKIP to Infant Feeding CP1 
HR2. HIV Test Result Today Negative Positive Inconclusive 
If Negative skip to CP1 
HR3. If Positive, ……  CD4 Test Done   Yes  No  
 Clinical Staging Done   Yes  No 
 NVP Dispensed    Yes  No 
 MVT Dispensed   Yes  No 
 AZT Dispensed   Yes  No 
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HR4. Results  CD4 Test Result   
 Clinical Staging   
 Date NVP Dispensed    __  __/__  __/__  __  
    D  D  M  M  Y  Y 
 
 Date MVT Dispensed     __  __/__  __/__  __  
      D  D  M  M  Y  Y 
 Date AZT Dispensed     __  __/__  __/__  __  
      D  D  M  M  Y  Y 
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SOUTH AFRICAN HIV ANTENATAL POSTTEST SUPPORT (SAHAPS) STUDY     MEDICAL CHART EXTRACTION FORM  VISIT: 6 WEEK (POSTNATAL)    
Study Screening # S 0 0 1    
Antenatal Number #        
 
Date of Visit       
      D            D          M        M          Y Y 
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DURATION OF HIV COUNSELING SESSIONS:  
 
2nd Post-test Counseling session 6 WEEK:  
Date of 2nd post-test counseling session:  __  __/__  __/__  __  
       D  D  M  M  Y  Y 
 
Time that the consultation started: ___________    Time HIV counseling started: 
___________ 
Time consultation ended: ___________    Time HIV counseling ended: 
___________  
 
 INFANT HEALTH 
IH1. Infant’s Condition Alive  Demised   
If demised SKIP to SB1 (SEXUAL BEHAVIOUR) 
IH2. Baby Weight .  kg 
IH3. Is infant fully immunized to-date? Yes No 
IH4. Infant Feeding Practice  
 
 
 
 Exclusive breastfeed 
       Exclusive formula  
        Breast and Other 
 Formula and Other 
       Breast and Formula  
 
IH5. Is infant HIV Exposed? Yes   No 
If No skip to SB1 (SEXUAL BEHAVIOUR). 
IH6. If Infant is HIV Exposed, was Bactrim 
Administered? 
Yes   No 
 
IH7. If Infant is HIV Exposed, was Infant tested by 
PCR for HIV? 
Yes   No 
 
 
SEXUAL BEHAVIOUR 
SB1. Since delivery have you had sex? Yes   No 
If No skip to SB6 
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SB2. When did you first have sex since delivery? 1 2 3 4 5       weeks after birth 
SB3. Since delivery how many times have you 
had sex? 
  times 
SB4. How many times have you used a condom?   times 
SB5. What method or methods of Contraception 
is she on? 
  Pill 
Injectables 
Male condom 
Female condom 
Tubal Ligation 
Other_specify______________________ 
 
SB6. Have you shared your HIV test results with 
your partner? 
Yes No 
SB7. Since you have tested for HIV, has your 
partner been tested for HIV? 
Yes No 
If No skip to DB1 (DELIVERY-BIRTH) 
SB8.What are his Test Result Positive   Negative    Do not know 
58 
 
DELIVERY-BIRTH OUTCOMES 
 
DB1. Date of Delivery 1. ___ ___ ___ ___ ___ ___ ___  
           D     D     M   M   M    Y    Y 
 
DB2. Gender of Baby  male   female  N/A 
DB3. Pregnancy Outcome   FSB  MSB LB  ENND 
DB4. Baby Birth Weight . kg 
DB5. Infant Feeding Practice at Birth 
 
 
 
 Exclusive breastfeed 
       Exclusive formula  
        Breast and Other 
 Formula and Other 
       Breast and Formula  
 N/A 
 
DB6. sd NVP Administered to Mum in Labour Yes No  N/A 
 
DB7. sd NVP Administered to Infant at Birth Yes No  N/A 
 
DB8. AZT Administered during Labour Yes No  N/A 
 
DB9. AZT Administered to Infant 7DAYS 28DAYS  NONE  N/A 
  
DB10. NVP Administered to Infant for 6 weeks Yes No  N/A 
 
  
DB11. HAART Initiated Yes No  N/A 
  
DB12. Date HAART Initiated D     D     M   M   M    Y    Y     N/A 
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SOUTH AFRICAN HIV ANTENATAL POSTTEST SUPPORT (SAHAPS) STUDY     MEDICAL CHART EXTRACTION FORM  VISIT: 14 WEEK (POSTNATAL)   
Study Screening # S 0 0 1    
Antenatal Number #        
 
Date of Visit       
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SEXUALLY TRANSMITTED INFECTIONS POSTNATALLY 
  
ST1.  STI Lab  
Investigations Done 
RPR      Yes  No    
 
TPHA   Yes  No   
 
CVS – Neisseria gonorrhea      Yes  No   
 
CVS – Trichomonas vaginalis  Yes  No   
 
CVS - Chlamydia trachomatis   Yes  No   
ST2.  STI Lab  
Investigations Results 
 
RPR Negative Positive Inconclusive Inadequate Specimen    
 
TPHA Negative Positive Inconclusive Inadequate Specimen 
 
CVS – N. gonorrhea Negative Positive Inconclusive Inadequate Specimen 
 
CVS T. vaginalis Negative Positive Inconclusive Inadequate Specimen 
 
CVS C. trachomatis Negative Positive Inconclusive Inadequate Specimen 
 
ST3.  Clinical Signs of 
STI (Discharge/ulcer 
etc)  
 
 Yes  No    
 
ST4. PAP smear done  Yes  No    
 
ST5. If Yes Results 
 
HIV RETESTING FOR WOMEN WHO TESTED NEGATIVE AT LAST TEST 
 
 
HR1. HIV Tested Today Yes  Refused 
If Yes SKIP to HR2.  
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HR2. If refused, why?   Did not perceive herself to be at risk   Afraid to test 
  Tested before   To discuss with partner 
  Other ____________________________________ 
SKIP to Infant Feeding CP1 
HR2. HIV Test Result Today Negative Positive Inconclusive 
If Negative skip to CP1 
HR3. If Positive, ……  CD4 Test Done   Yes  No  
 Clinical Staging Done   Yes  No 
 NVP Dispensed    Yes  No 
 HAART Initiated  Yes  No 
HR4. Results  CD4 Test Result   
 Clinical Staging   
 Date NVP Dispensed    __  __/__  __/__  __  
    D  D  M  M  Y  Y 
 
 Date MVT Dispensed     __  __/__  __/__  __  
      D  D  M  M  Y  Y 
 Date AZT Dispensed     __  __/__  __/__  __  
      D  D  M  M  Y  Y 
 Date HAART Dispensed     __  __/__  __/__  __  
      D  D  M  M  Y  Y 
 
 
 
 INFANT HEALTH 
 
IH1. Infant Feeding Practice  
 
 
 
 Exclusive breastfeed 
       Exclusive formula  
        Breast and Other 
 Formula and Other 
       Breast and Formula  
 
 
DB1. NVP Administered to Infant Yes No  N/A 
 
 
62 
 
APPENDIX 8: PUBLISHED MANUSCRIPT 
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